Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER IMMUNOTHERAPY

In CAR T cell-treated lymphomas, the T cell rich get richer

Nature Medicine volume 28, pages 1757–1758 (2022)Cite this article

Subjects

In patients with large B cell lymphomas, immune features of the tumor microenviroment predict clinical outcomes after CAR T cell therapy; as the number of patients treated with CAR T cells is set to increase, refinement of these and other biomarkers will be crucial.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The immune content of the TME of LBCL is associated with clinical outcomes after CAR T cell therapy.

References

  1. Neelapu, S. S. et al. N. Engl. J. Med. 377, 2531–2544 (2017).

    Article  CAS  Google Scholar 

  2. Shalabi, H. et al. Haematologica 103, e215–e218 (2018).

    Article  CAS  Google Scholar 

  3. Kline, J., Godfrey, J. & Ansell, S. M. Blood 135, 523–533 (2020).

    Article  CAS  Google Scholar 

  4. Bruni, D., Angell, H. K. & Galon, J. Nat. Rev. Cancer 20, 662–680 (2020).

    Article  CAS  Google Scholar 

  5. Scholler, N. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01916-x (2022).

    Article  PubMed  Google Scholar 

  6. Locke, F. L. et al. Blood Adv. 4, 4898–4911 (2020).

    Article  CAS  Google Scholar 

  7. Cao, Y. et al. Front. Oncol. 9, 767 (2019).

    Article  Google Scholar 

  8. Hawkins, E. R., D’Souza, R. R. & Klampatsa, A. Biologics 15, 95–105 (2021).

    PubMed  PubMed Central  Google Scholar 

  9. Sterner, R. C. & Sterner, R. M. Blood Cancer J. 11, 69 (2021).

    Article  Google Scholar 

  10. Locke, F. L. et al. N. Engl. J. Med. 386, 640–654 (2021).

    Article  Google Scholar 

  11. Neelapu, S. S. et al. Nat. Med. 28, 735–742 (2022).

    Article  CAS  Google Scholar 

  12. Lacy, S. E. et al. Blood 135, 1759–1771 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Theodora Anagnostou & Joshua D. Brody

  2. Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Joshua D. Brody

  3. Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, USA

    Joshua D. Brody

Authors
  1. Theodora Anagnostou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua D. Brody
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joshua D. Brody.

Ethics declarations

Competing interests

J.D.B. receives research funding or non-financial support from: Merck, Genentech, Kite/Gilead, SeaGen, Astrazeneca, ADC Therapeutics, Epizyme, Celldex Therapeutics and Oncovir.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anagnostou, T., Brody, J.D. In CAR T cell-treated lymphomas, the T cell rich get richer. Nat Med 28, 1757–1758 (2022). https://doi.org/10.1038/s41591-022-01922-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-01922-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research